Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction

Author(s): Yuyi Yuan, Hui Wu, Bo Shuai, Chang Liu, Feng Zhu, Fei Gao, Chunzhu Wei and Heng Fan*

Volume 28, Issue 42, 2022

Published on: 28 November, 2022

Page: [3456 - 3468] Pages: 13

DOI: 10.2174/1381612829666221122113929

Price: $65

Abstract

Background: The mechanism of Heat Shock Protein 90 (HSP90) in Ulcerative Colitis (UC) has been studied, and mitogenic-activated protein kinases (MAPK) also contribute to the pathogenesis of UC. However, the effect of the HSP90/MAPK pathway in UC is still unclear. Therefore, the mainstay of this research is to explore the mechanism of action of this pathway in UC. Compound sophorae decoction (CSD), as a Chinese herbal decoction, can synergistically affect the above process.

Objective: This study aimed to uncover the synergistic effects of HSP90 inhibitors regulating the MAPK pathway for treating DSS-induced colitis in mice and the synergistic effects of CSD.

Methods: This experiment used oral administration of standard diets containing 3% dextran sodium sulfate (DSS) to establish an experimental colitis model in mice. The model was treated with HSP90 inhibitor, CSD, or dexamethasone. Mouse feces, mobility, body weight, colon length, and colon histopathology scores were recorded daily to assess the degree of colitis inflammation. Expression levels of HSP90 and MAPK pathway-related genes and proteins were evaluated by Western blot and qPCR. The evaluation of intestinal mucosal permeability was measured by enzyme-linked immunosorbent assay (ELISA), which could detect the protein level of D-Amino Acid Oxidase (DAO) and D-lactic acid (D-LA). The same went for downstream molecules AFT-2, p53, and apoptosis-related proteins BAX, BCL-2, Caspase3, and survivin in the MAPK pathway. Immunohistochemical measured p-38, p-JNK, and p-ERK expressions. JAM-A and claudin-1 connexin were tested by immunofluorescence staining. The TUNEL method was for measuring the apoptosis rate of colonic epithelial cells. CBA kit determined the level of inflammatory factors of colons.

Results: HSP90 inhibitor can improve the degree of pathological damage in the colon of mice treated with DSS, increase the mice's weight and the length of the colon, and significantly reduce the disease activity index (DAI) score. Intraperitoneal injection of HSP90 inhibitor can reduce the expression of MAPK pathway markers P38, JNK, ERK, and their phosphorylation and decrease the content of AFT-2 and p53, which is downstream of the MAPK pathway. In addition, treatment of the HSP90 inhibitor up-regulated the expression of anti-apoptotic proteins BCL-2 and survivin, as well as down-regulated apoptotic protein caspase3, BAX in the colon of mice with colitis. Lower levels of inflammatory factors such as IL-6, MCP-1, IFN-γ, TNF, IL-12p70, and increased IL-10 were observed after HSP90 inhibitor therapy. Furthermore, the combination treatment of CSD can enhance the effect of the single HSP90 inhibitor treatment and play a synergistic effect.

Conclusion: These data suggest that an HSP90 inhibitor is available to treat UC by inhibiting the MAPK signaling pathway. This axis can restore the intestinal mucosa barrier's function by reducing intestinal mucosa's permeability and inhibiting apoptosis of intestinal epithelial cells. The specific mechanism is that HSP90 inhibitor can reduce the pathological damage and inflammation levels of colitis mice, and reduce the apoptosis rate of colonic epithelial cells and the mucosal permeability, thereby restoring the mucosal barrier function. During this process, CSD works synergistically to improve the therapeutic effect of the HSP90 inhibitor.

Erratum In:
Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction

« Previous
[1]
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017; 389(10080): 1756-70.
[http://dx.doi.org/10.1016/S0140-6736(16)32126-2] [PMID: 27914657]
[2]
Kampinga HH, Hageman J, Vos MJ, et al. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009; 14(1): 105-11.
[http://dx.doi.org/10.1007/s12192-008-0068-7] [PMID: 18663603]
[3]
Scieglinska D, Krawczyk Z, Sojka DR, Gogler-Pigłowska A. Heat shock proteins in the physiology and pathophysiology of epidermal keratinocytes. Cell Stress Chaperones 2019; 24(6): 1027-44.
[http://dx.doi.org/10.1007/s12192-019-01044-5] [PMID: 31734893]
[4]
Wiech H, Buchner J, Zimmermann R, Jakob U. Hsp90 chaperones protein folding in vitro. Nature 1992; 358(6382): 169-70.
[http://dx.doi.org/10.1038/358169a0] [PMID: 1614549]
[5]
Treweek TM, Meehan S, Ecroyd H, Carver JA. Small heat-shock proteins: important players in regulating cellular proteostasis. Cell Mol Life Sci 2015; 72(3): 429-51.
[http://dx.doi.org/10.1007/s00018-014-1754-5] [PMID: 25352169]
[6]
de Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011; 31(10): 2066-78.
[http://dx.doi.org/10.1128/MCB.05155-11] [PMID: 21444725]
[7]
Hoter A, Naim HY. The functions and therapeutic potential of heat shock proteins in inflammatory bowel disease—an update. Int J Mol Sci 2019; 20(21): 5331.
[http://dx.doi.org/10.3390/ijms20215331] [PMID: 31717769]
[8]
Tomasello G, Sciumé C, Rappa F, et al. Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy. Eur J Histochem 2011; 55(4): e38.
[http://dx.doi.org/10.4081/ejh.2011.e38] [PMID: 22297444]
[9]
Chen R, Pan S, Lai K, et al. Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancer. World J Gastroenterol 2014; 20(45): 17037-48.
[http://dx.doi.org/10.3748/wjg.v20.i45.17037] [PMID: 25493016]
[10]
Collins CB, Strassheim D, Aherne CM, Yeckes AR, Jedlicka P, de Zoeten EF. Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation. Inflamm Bowel Dis 2014; 20(4): 685-94.
[http://dx.doi.org/10.1097/01.MIB.0000442839.28664.75] [PMID: 24552830]
[11]
Collins CB, Aherne CM, Yeckes A, et al. Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function. Mucosal Immunol 2013; 6(5): 960-71.
[http://dx.doi.org/10.1038/mi.2012.134] [PMID: 23321985]
[12]
Kim BW, More SV, Yun YS, et al. A novel synthetic compound MCAP suppresses LPS-induced murine microglial activation in vitro via inhibiting NF-kB and p38 MAPK pathways. Acta Pharmacol Sin 2016; 37(3): 334-43.
[http://dx.doi.org/10.1038/aps.2015.138] [PMID: 26838070]
[13]
Lee KC, Chen WT, Liu YC, Lin SS, Hsu FT. Amentoflavone inhibits hepatocellular carcinoma progression through blockage of ERK/NF-ĸB activation. In Vivo 2018; 32(5): 1097-103.
[http://dx.doi.org/10.21873/invivo.11351] [PMID: 30150431]
[14]
Bai XS, Bai G, Tang LD, Li Y, Huan Y, Wang H. MiR-195 alleviates ulcerative colitis in rats via MAPK signaling pathway. Eur Rev Med Pharmacol Sci 2020; 24(5): 2640-6.
[PMID: 32196614]
[15]
Tamura S, Marunouchi T, Tanonaka K. Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway. J Mol Cell Cardiol 2019; 127: 134-42.
[http://dx.doi.org/10.1016/j.yjmcc.2018.12.010] [PMID: 30582930]
[16]
Wu H, Chen QY, Wang WZ, et al. Compound sophorae decoction enhances intestinal barrier function of dextran sodium sulfate induced colitis via regulating notch signaling pathway in mice. Biomed Pharmacother 2021; 133: 110937.
[http://dx.doi.org/10.1016/j.biopha.2020.110937] [PMID: 33217689]
[17]
Zhu F, Li H, Liu Y, et al. miR-155 antagomir protect against DSS-induced colitis in mice through regulating Th17/Treg cell balance by Jarid2/Wnt/β-catenin. Biomed Pharmacother 2020; 126: 109909.
[http://dx.doi.org/10.1016/j.biopha.2020.109909] [PMID: 32135463]
[18]
Erlichman C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs 2009; 18(6): 861-8.
[http://dx.doi.org/10.1517/13543780902953699] [PMID: 19466875]
[19]
Nunes NS, Chandran P, Sundby M, et al. Therapeutic ultrasound attenuates DSS-induced colitis through the cholinergic anti-inflammatory pathway. EBioMedicine 2019; 45: 495-510.
[http://dx.doi.org/10.1016/j.ebiom.2019.06.033] [PMID: 31253515]
[20]
He C, Yu T, Shi Y, et al. MicroRNA 301A promotes intestinal inflammation and colitis-associated cancer development by inhibiting BTG1. Gastroenterology 2017; 152(6): 1434-1448.e15.
[http://dx.doi.org/10.1053/j.gastro.2017.01.049] [PMID: 28193514]
[21]
Gao W, Wang C, Yu L, et al. Chlorogenic acid attenuates dextran sodium sulfate-induced ulcerative colitis in mice through MAPK/ERK/JNK pathway. BioMed Res Int 2019; 2019: 1-13.
[http://dx.doi.org/10.1155/2019/6769789] [PMID: 31139644]
[22]
Wilcz-Villega EM, McClean S, O’Sullivan MA. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. Am J Gastroenterol 2013; 108(7): 1140-51.
[http://dx.doi.org/10.1038/ajg.2013.92] [PMID: 23588236]
[23]
Xue M, Ji X, Liang H, et al. The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer. Food Funct 2018; 9(2): 1214-23.
[http://dx.doi.org/10.1039/C7FO01677H] [PMID: 29384543]
[24]
Gancarcikova S, Lauko S, Hrckova G, et al. Innovative Animal Model of DSS-Induced Ulcerative Colitis in Pseudo Germ-Free Mice. Cells 2020; 9(12): 2571.
[http://dx.doi.org/10.3390/cells9122571] [PMID: 33271873]
[25]
Taghadosi M, Adib M, Jamshidi A, Mahmoudi M, Farhadi E. The p53 status in rheumatoid arthritis with focus on fibroblast-like synoviocytes. Immunol Res 2021; 69(3): 225-38.
[http://dx.doi.org/10.1007/s12026-021-09202-7] [PMID: 33983569]
[26]
Guo H, Lei H, Zhang BG, Xu ZC, Dong C, Hao YQ. c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 is a critical regulator for arthritis progression by meditating inflammation in mice model. Int Immunopharmacol 2020; 81: 106272.
[http://dx.doi.org/10.1016/j.intimp.2020.106272] [PMID: 32062074]
[27]
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012; 380(9853): 1606-19.
[http://dx.doi.org/10.1016/S0140-6736(12)60150-0] [PMID: 22914296]
[28]
Stah M, Ludwig D, Fellermann K, Stange EF. Intestinal expression of human heat shock protein 90 in patients with Crohn’s disease and ulcerative colitis. Dig Dis Sci 1998; 43(5): 1079-87.
[http://dx.doi.org/10.1023/A:1018847205420] [PMID: 9590425]
[29]
Tlaskalová-Hogenová H, Štěpánková R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93(2-3): 97-108.
[http://dx.doi.org/10.1016/j.imlet.2004.02.005] [PMID: 15158604]
[30]
Yang M, Zhang F, Yang C, et al. Oral targeted delivery by nanoparticles enhances efficacy of an HSP90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer. J Crohn’s Colitis 2020; 14(1): 130-41.
[http://dx.doi.org/10.1093/ecco-jcc/jjz113] [PMID: 31168612]
[31]
Hong LJ, Chen AJ, Li FZ, Chen KJ, Fang S. The HSP90 inhibitor, 17-AAG, influences the activation and proliferation of T lymphocytes via AKT/GSK3β signaling in MRL/lpr mice. Drug Des Devel Ther 2020; 14: 4605-12.
[http://dx.doi.org/10.2147/DDDT.S269725] [PMID: 33149557]
[32]
Qin JH, Wang K, Fu XL, et al. Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt/NF-κB signaling. Oncol Rep 2017; 38(3): 1517-24.
[http://dx.doi.org/10.3892/or.2017.5797] [PMID: 28713903]
[33]
Hu L, Wang Y, Chen Z, et al. HSP90 inhibitor SNX-2112 enhances TRAIL-induced apoptosis of human cervical cancer cells via the ROS-mediated JNK-p53-autophagy-DR5 pathway. Oxid Med Cell Longev 2019; 2019: 1-26.
[http://dx.doi.org/10.1155/2019/9675450] [PMID: 31019655]
[34]
Zhao Y, Li K, Zhao B, Su L. HSP90 inhibitor DPB induces autophagy and more effectively apoptosis in A549 cells combined with autophagy inhibitors. In vitro Cell Dev Biol Anim 2019; 55(5): 349-54.
[http://dx.doi.org/10.1007/s11626-019-00327-6] [PMID: 30989449]
[35]
Sui X, Kong N, Ye L, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett 2014; 344(2): 174-9.
[http://dx.doi.org/10.1016/j.canlet.2013.11.019] [PMID: 24333738]
[36]
Kumar R, Gupta YK, Singh S, Patil A. Glorisa superba hydroalcoholic extract from tubers attenuates experimental arthritis by downregulating inflammatory mediators, and phosphorylation of ERK/JNK/p-38. Immunol Invest 2016; 45(7): 603-18.
[http://dx.doi.org/10.1080/08820139.2016.1195406] [PMID: 27603689]
[37]
Gao Z, Yu C, Liang H, et al. Andrographolide derivative CX-10 ameliorates dextran sulphate sodium-induced ulcerative colitis in mice: Involvement of NF-κB and MAPK signalling pathways. Int Immunopharmacol 2018; 57: 82-90.
[http://dx.doi.org/10.1016/j.intimp.2018.02.012] [PMID: 29475099]
[38]
Xu M, Duan XY, Chen QY, et al. Effect of compound sophorae decoction on dextran sodium sulfate (DSS)-induced colitis in mice by regulating Th17/Treg cell balance. Biomed Pharmacother 2019; 109: 2396-408.
[http://dx.doi.org/10.1016/j.biopha.2018.11.087] [PMID: 30551499]
[39]
Otani T, Nguyen TP, Tokuda S, et al. Claudins and JAM-A coordinately regulate tight junction formation and epithelial polarity. J Cell Biol 2019; 218(10): 3372-96.
[http://dx.doi.org/10.1083/jcb.201812157] [PMID: 31467165]
[40]
Tay KC, Tan LTH, Chan CK, et al. Formononetin: A review of its anticancer potentials and mechanisms. Front Pharmacol 2019; 10: 820.
[http://dx.doi.org/10.3389/fphar.2019.00820] [PMID: 31402861]
[41]
Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2013; 332(2): 313-24.
[http://dx.doi.org/10.1016/j.canlet.2011.01.012] [PMID: 21345578]
[42]
Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 2015; 5: 288.
[http://dx.doi.org/10.3389/fonc.2015.00288] [PMID: 26732534]
[43]
Sun P, Wang Y, Gao T, et al. Hsp90 modulates human sperm capacitation via the Erk1/2 and p38 MAPK signaling pathways. Reprod Biol Endocrinol 2021; 19(1): 39.
[http://dx.doi.org/10.1186/s12958-021-00723-2] [PMID: 33663544]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy